Top

Published in:

Open Access 01-05-2019 | Neurological Update

Neurological update: MOG antibody disease

Authors: Ray Wynford-Thomas, Anu Jacob, Valentina Tomassini

Published in: Journal of Neurology | Issue 5/2019

Abstract

Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is now recognised as a nosological entity with specific clinical and paraclinical features to aid early diagnosis. Although no age group is exempt, median age of onset is within the fourth decade of life, with optic neuritis being the most frequent presenting phenotype. Disease course can be either monophasic or relapsing, with subsequent relapses most commonly involving the optic nerve. Residual disability develops in 50–80% of patients, with transverse myelitis at onset being the most significant predictor of long-term outcome. Recent advances in MOG antibody testing offer improved sensitivity and specificity. To avoid misdiagnosis, MOG antibody testing should be undertaken in selected cases presenting clinical and paraclinical features that are felt to be in keeping with MOG-AD, using a validated cell-based assay. MRI characteristics can help in differentiating MOG-AD from other neuroinflammatory disorders, including multiple sclerosis and neuromyelitis optica. Cerebrospinal fluid oligoclonal bands are uncommon. Randomised control trials are limited, but observational open-label experience suggests a role for high-dose steroids and plasma exchange in the treatment of acute attacks, and for immunosuppressive therapies, such as steroids, oral immunosuppressants and rituximab as maintenance treatment.

Schluesener H et al (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 139(12):4016–4021PubMed

Bernard C et al (1997) Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 75(2):77–88CrossRefPubMed

Johns T, Bernard C (1999) The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72(1):1–9CrossRefPubMed

Linington C, Lassmann H (1987) Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol 17(1):61–69CrossRefPubMed

Linington C et al (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130(3):443–454PubMedPubMedCentral

Karni A et al (1999) Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 56(3):311–315CrossRefPubMed

Tomassini V et al (2007) Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 13(9):1086–1094CrossRefPubMed

Berger T et al (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139–145CrossRefPubMed

Rauer S et al (2006) Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 77:739–742CrossRefPubMedPubMedCentral

10.

Pittock S et al (2007) Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 13(1):7–16CrossRefPubMed

11.

Kuhle J et al (2007) Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 356(4):371–378CrossRefPubMed

12.

Tanaka M, Tanaka K (2014) Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol 270(1–2):98–99CrossRefPubMed

13.

Waters P et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2(3):e89CrossRefPubMedPubMedCentral

14.

Wingerchuk D et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189CrossRefPubMedPubMedCentral

15.

Thompson A et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173CrossRefPubMed

16.

Jarius S et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflamm 15:134CrossRef

17.

Hacohen Y et al (2017) Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology 89(3):269–278CrossRefPubMed

18.

Mariotto S et al (2017) Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol 264(12):2420–2430CrossRefPubMedPubMedCentral

19.

Kezuka T, Ishikawa H (2018) Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. Jpn J Ophthalmol 62(2):101–108CrossRefPubMed

20.

Hennes E et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900–908CrossRefPubMed

21.

Wong Y et al (2018) Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. Eur J Neurol 25(5):782–786CrossRefPubMed

22.

Spadaro M et al (2015) Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2(3):295–301CrossRefPubMedPubMedCentral

23.

Zhou L et al (2017) Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies. Mult Scler Relat Disord 18:90–92CrossRefPubMed

24.

Zhou J et al (2018) An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis. J Neuroimmunol. https://doi.org/10.1016/j.jneuroim.2018.03.019. (Epub ahead of print) CrossRefPubMedPubMedCentral

25.

Nakamura M et al (2017) A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. Mult Scler Relat Disord 17:148–150CrossRefPubMed

26.

Vieira J, Sequeira J, Brito M (2017) Postinfectious anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis and myelitis. J Child Neurol 32(12):996–999CrossRefPubMed

27.

Nakamura Y et al (2017) Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report. BMC Neurol 17(1):76CrossRefPubMedPubMedCentral

28.

Peschl P et al (2017) Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflamm 14:208CrossRef

29.

Cobo-Calvo A et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. https://doi.org/10.1212/WNL.0000000000005560. (Epub ahead of print) CrossRefPubMed

30.

Cobo-Calvo A et al (2017) MOG antibody-related disorders: common features and uncommon presentations. J Neurol 264(9):1945–1955CrossRefPubMed

31.

Ramanathan S et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89:127–137CrossRefPubMed

32.

Jurynczyk M et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128–3138CrossRefPubMed

33.

Jarius S et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm 13:280CrossRef

34.

Ramanathan S et al (2015) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J 22(4):470–482CrossRef

35.

Biotti D et al (2017) Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol 264(10):2173–2175CrossRefPubMed

36.

Hamid S et al (2018) Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol 75(1):65–71CrossRefPubMed

37.

Hacohen Y et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody–associated disease. JAMA Neurol 75(4):478–487CrossRefPubMedPubMedCentral

38.

Ogawa R et al (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4(2):e322CrossRefPubMedPubMedCentral

39.

Stiebel-Kalish H et al (2017) Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS One 12(1):e0170847CrossRefPubMedPubMedCentral

40.

Pache F et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm 13:282CrossRef

41.

Jurynczyk M et al (2015) Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry 86:20–25CrossRefPubMed

42.

Kalincik T et al (2014) Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler 20(11):1511–1522CrossRefPubMed

43.

Matthews L et al (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80(14):1330–1337CrossRefPubMedPubMedCentral

44.

Tomassini V, Palace J (2009) Multiple sclerosis lesions: insights from imaging techniques. Expert Rev Neurother 9(9):1341–1359CrossRefPubMed

45.

Wingerchuk D et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815CrossRefPubMed

46.

Jurynczyk M et al (2017) Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 140(3):617–627CrossRefPubMed

47.

Spadaro M et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(5):e257CrossRefPubMedPubMedCentral

48.

Jarius S et al (2016) Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler J 22(12):1541–1549CrossRef

Title: Neurological update: MOG antibody disease
Authors: Ray Wynford-Thomas
Anu Jacob
Valentina Tomassini
Publication date: 01-05-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 5/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-9122-2

At a glance: The STEP trials

Springer Medicine

Neurological update: MOG antibody disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Crossed aphasia confirmed by fMRI in a case with nonfluent variant of primary progressive aphasia carrying a GRN mutation

Lifestyles correlate with stroke recurrence in Chinese inpatients with first-ever acute ischemic stroke

Misdiagnoses and delay of diagnoses in Moyamoya angiopathy—a large Caucasian case series

Dissecting the neurological phenotype in children with callosal agenesis, interhemispheric cysts and malformations of cortical development

Autoimmune encephalitis: frequency and prognosis

Defining metronidazole-induced encephalopathy